LYCA

Lycia Therapeutics Inc

26.40

Oct 30 • 3:59 PM ET -1.33 (-4.80%)

26.92

Aftermarket • 7:51 PM ET +0.52 (1.97%)

Healthcare Biotechnology USA Small NASD

Index	-
Market Cap	1.52B
Enterprise Value	-
Income	-
Sales	-
Book/sh	-
Cash/sh	-
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Oct 23, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	-
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	-
Current Ratio	-
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	-
Insider Trans	-
Inst Own	12.93%
Inst Trans	-
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-3.50%
SMA50	-3.50%
SMA200	-3.50%
Trades

Shs Outstand	55.03M
Shs Float	-
Short Float	-
Short Ratio	-
Short Interest	-
52W High	36.49 -27.66%
52W Low	22.19 18.97%
Volatility	15.03% -
ATR (14)	5.59
RSI (14)	-
Beta	-
Rel Volume	0.24
Avg Volume	747.92K
Volume	202,230

Perf Week	-12.00%
Perf Month	-
Perf Quarter	-
Perf Half Y	-
Perf YTD	-7.53%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	27.73
Price	26.40
Change %	-4.80%

Oct-26-26 04:12PM	Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -9.50%
Oct-24-26 02:56PM	Forget Anthropic: Biotech Is Quietly Dominating the IPO Sphere (Barrons.com)
Oct-23-26 01:03PM	Lycia Therapeutics surges in debut following upsized $317.5M IPO (Investing.com)

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Venrock Healthcare Capital Par	10% Owner	Oct 28 '26	Buy	25.45	15,000	381,728	6,840,233	Oct 30 07:25 PM
Venrock Healthcare Capital Par	10% Owner	Oct 30 '26	Buy	26.28	9,004	236,653	6,850,237	Oct 30 07:25 PM
Venrock Healthcare Capital Par	10% Owner	Oct 29 '26	Buy	26.33	1,000	26,330	6,841,233	Oct 30 07:25 PM
Venrock Healthcare Capital Par	10% Owner	Oct 26 '26	Buy	18.04	1,952,705	35,222,791	6,785,437	Oct 27 06:38 PM
Venrock Healthcare Capital Par	10% Owner	Oct 23 '26	Buy	25.91	52,939	1,371,676	52,939	Oct 27 06:38 PM
Venrock Healthcare Capital Par	10% Owner	Oct 27 '26	Buy	26.62	39,796	1,059,396	6,825,233	Oct 27 06:38 PM

Lycia Therapeutics, Inc. operates as a clinical-stage biotechnology company. It engages in the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory, and allergic diseases. The company was founded in 2019 and is headquartered in South San Francisco, CA.

CEODr. Aetna Wun Trombley Ph.D.

Ph.D.Dr. Carolyn R. Bertozzi M.S.

Chief Financial OfficerMs. Amy Bachrodt

VP & Head of BiologicsMr. Darrin Lindhout Ph.D.

Chief Business OfficerMs. Sofia Touami Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LYCA

Lycia Therapeutics Inc

Upgrade your Finviz experience